TheraRadar
Clinical-Stage Companies / Repurposed

Repurposed

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 8/23/2022

9
Total Trials
7
Phase 3
4
Phase 2
2
Recruiting
137
Score

Pipeline by Phase

Phase 3
7
Phase 2
4
Phase 1

Therapeutic Focus

Motion Sickness Motion Sickness, Space Sea Sickness Motion Simulation Parabolic Flight

Clinical Trials (9)

NCT03988530 Phase 3 COMPLETED

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Started: 6/7/2019

NCT05548270 Phase 3 COMPLETED

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Started: 8/23/2022

NCT04947423 Phase 3 COMPLETED

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Started: 6/14/2021

NCT03986905 Phase 3 COMPLETED

The Prevention and Treatment of Nausea Associated With Motion Sickness

Started: 4/26/2019

NCT04184115 Phase 3 COMPLETED

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

Started: 6/9/2019

NCT05886660 Phase 2 RECRUITING

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Started: 1/21/2022

NCT05852730 Phase 2 RECRUITING

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Started: 8/10/2021

NCT04219982 Phase 2 TERMINATED

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

Started: 6/29/2018

NCT02155309 Phase 2 TERMINATED

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

Started: 6/1/2014

Drug Candidates

DPI-386 Nasal Gel Placebo Nasal Gel Other (e.g., promethazine, meclizine) Scopolamine Placebo DPI-386 Placebo Nasal Gel Transderm Scop® Scopolamine Nasal Gel Placebos
Activity Status: Inactive
Last Trial Started: 8/23/2022
Last Trial Ended: 11/29/2022
Trials (12 months): 0
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.